Browse studies

Find your next paid study

7 recruiting studies matching your filters

Phase 1b/2 Study of Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer

By doing this study, it is the hope to learn whether an injection of the measles, mumps, rubella (MMR) vaccine developed by Merck \& Co. (Merck's M-M-R® II) in…

Borderline Resectable/Unresectable Pancreatic CancerNon Metastatic Pancreatic Cancer

Estimated

~$10 – $6,250

University of ArkansasNCT07539155

Observational

A Randomized, Multicenter, Multiregional, Pivotal Clinical Trial to Evaluate the Safety and Efficacy of IMD10 (Focused Ultrasound) in Combination With the Chemotherapy Regimen Consisting of Irinotecan Hydrochloride, Oxaliplatin, Fluorouracil (5-FU) and Leucovorin Improves Overall Survival Compared With the Chemotherapy Regimen Alone in Patients With Borderline Resectable Pancreatic Cancer or Locally Advanced Pancreatic Cancer

The purpose of this Interventional clinical trial is to evaluate safety and efficacy of 'IMD10 (focused ultrasound)' in the treatment of borderline resectable …

Pancreatic CancerBorderline Resectable Pancreatic CancerLocally Advanced Pancreatic Cancer

Estimated

~$10 – $8,750

IMGT Co., Ltd.NCT07325214

Phase 1

Nano-SMART: An Adaptive Phase I-II Trial of AGuIX Gadolinium-based Nanoparticles With Stereotactic Magnetic Resonance-guided Adaptive Radiation Therapy for Centrally Located Lung Tumors and Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma

This research study is being done to help determine the safety and efficacy of gadolinium based nanoparticle, Activation and Guidance of Irradiation X (AGuIX),…

Non-small Cell Lung CancerAdvanced Pancreatic AdenocarcinomaUnresectable Pancreatic Cancer+1 more

Estimated

~$10 – $7,500

Dana-Farber Cancer InstituteNCT04789486

Phase 2

A Phase II Study of Peri-Operative NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

This is a single arm phase II study. All patients will receive 3 cycles of the treatment of nab-paclitaxel (Days 1, 8 and 15), gemcitabine (Days 1, 8 and 15), …

Pancreatic AdenocarcinomaResectable Pancreatic Cancer

Estimated

~$10 – $7,500

Ashish ManneNCT05624918

Phase 2

A Phase II Trial of Pre-operative Chemotherapy (With Gemcitabine and Nab- Paclitaxel) and Stereotactic Body Radiotherapy Followed by Surgery and Chemotherapy in Patients With Resectable Pancreatic Adenocarcinoma

The purpose of this phase 2 research study is to determine whether a combination of chemotherapy drugs plus radiation therapy, given before surgery in resectab…

Pancreas AdenocarcinomaResectable Pancreatic Cancer

Estimated

~$10 – $6,250

Loma Linda UniversityNCT03492671

Observational

DCE-MRI Guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer

The goal of this study is to test whether chemotherapy guided by a new imaging method named DCE-MRI can more effectively reduce a pancreatic tumor, enabling cu…

Borderline-resectable Pancreatic Cancer

Estimated

~$10 – $6,250

Ohio State UniversityNCT06173310

Phase 1

PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP): A Phase Ib/II Open-Label Trial

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor survival outcomes, even when treated with modern chemotherapy and radiation. Patients…

Pancreatic Ductal Adenocarcinoma (PDAC)Borderline Resectable Pancreatic CancerPancreatic Neoplasms

Estimated

~$10 – $6,250

University of VermontNCT07477418